Form 144 Filed for 1.5M Trulieve Shares, Insiders Trim Cannabis Holdings
15h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
trulieveform-144
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
A Form 144 filed with the SEC for the sale of 1.5 million shares of Trulieve Cannabis Corp. was reported on 17 June 2026. The planned disposition, reported by investing.com, represents a significant block of stock from company insiders. Based on Trulieve's recent trading price near $19.00, the total potential value of the transaction exceeds $28.5 million. The filing indicates a potential increase in the public float of one of the largest United States cannabis operators.
The filing arrives during a period of heightened sensitivity for multi-state operators regarding capital access and insider liquidity. The last comparable large Form 144 filing for a major US cannabis operator occurred in August 2025 when Curaleaf executives registered to sell approximately 2 million shares. That filing preceded a 14% sector-wide decline over the subsequent six weeks as broader market sentiment turned risk-off.
The current macro backdrop features elevated interest rates, with the 10-year Treasury yield holding above 4.2%. This environment pressures highly leveraged growth sectors like cannabis, which often rely on expensive debt financing. Recent volatility in the AdvisorShares Pure US Cannabis ETF MSOS, which holds Trulieve as a top component, underscores the sector's sensitivity to regulatory news flow and capital market conditions.
The trigger for the current insider filing likely stems from a combination of factors. Trulieve's stock appreciated by over 40% from its 2026 Q1 lows, creating a potential window for planned sales. The company recently completed a major debt refinancing round in May 2026, an event that often precedes pre-scheduled selling by executives whose compensation is heavily equity-based. The filing also precedes the Q2 earnings season, a typical blackout period for insider transactions.
The filed quantity of 1.5 million shares represents a substantial portion of Trulieve's daily trading volume. The company's average daily volume over the last 30 sessions is approximately 2.8 million shares. This planned sale equates to more than half of a typical day's liquidity, which could introduce volatility during the execution period. Trulieve's current market capitalization stands near $3.8 billion, making it the second-largest US cannabis operator by market value.
Insider ownership at Trulieve has been historically high. Before this filing, insiders and major beneficial owners controlled roughly 35% of the outstanding float. The proposed sale would reduce this concentrated ownership by approximately 1.4 percentage points. The stock is trading 22% below its 52-week high of $24.30 but remains 65% above its 52-week low of $11.50.
| Metric | Trulieve | MSOS ETF (Sector Benchmark) | SPY (Broad Market) |
|---|---|---|---|
| YTD Performance | +12.5% | +8.2% | +6.8% |
| Short Interest % of Float | 9.1% | N/A | 1.2% |
| Debt-to-Enterprise Value | 0.31 | 0.28 | 0.15 |
The company's price-to-sales ratio of 1.8x is below the sector average of 2.1x for profitable MSOs. This discount reflects investor concerns over its exposure to specific state markets like Florida, where recreational legalization efforts have stalled. Trulieve's operational footprint spans 11 states with 186 retail locations, generating over $1.3 billion in trailing twelve-month revenue.
The filing signals a potential near-term supply overhang for Trulieve stock, which could pressure its relative performance against peers like Green Thumb Industries and Curaleaf. A sustained sell-off in TCNNF could drag down the MSOS ETF, where it is a 12% holding. Conversely, the sale may create a buying opportunity for institutional funds awaiting a larger public float to establish or increase positions, providing a potential floor for the stock.
A key limitation to interpreting a single Form 144 is that it is a notice of intent, not a confirmation of completed sales. Insiders may sell only a portion of the registered shares, or none at all, depending on market conditions. The filing could also be part of a pre-arranged 10b5-1 trading plan established months prior, designed to remove discretion from the transaction timing and mitigate accusations of trading on material non-public information.
The flow effect is likely concentrated within the cannabis equity sector. Tactical traders may short Trulieve against a long position in a peer like Cresco Labs, betting on relative underperformance. Long-only funds focused on the sector may temporarily reduce their Trulieve weighting, reallocating to names with less imminent supply pressure. Options activity indicates a rise in put volume for July and August expiries, suggesting some investors are hedging against downside volatility.
The execution window for the Form 144 shares is the immediate focus. Investors will monitor daily volume and block trade reports for evidence of sales, which typically occur over several weeks. The next major catalyst is Trulieve's Q2 2026 earnings report, expected in the first week of August. Key metrics to watch will be free cash flow generation and same-store sales growth in core markets.
Specific price levels for Trulieve stock provide technical signposts. A sustained break below the 50-day moving average near $18.50 could signal further weakness toward the $17.00 support level. Conversely, absorption of selling pressure above $19.50 would indicate strong underlying demand. The relative strength of the MSOS ETF against the Russell 2000 small-cap index will indicate whether the selling is isolated or sector-wide.
Legislative catalysts remain critical for the entire sector. Progress on the SAFER Banking Act, with a potential committee vote scheduled for late July 2026, could overshadow near-term technical pressure from insider sales. State-level developments, particularly regarding adult-use legislation in Florida and Pennsylvania, will directly impact Trulieve's long-term growth trajectory and valuation multiples.
A Form 144 is a mandatory notification filed with the SEC when corporate insiders like officers, directors, or major shareholders plan to sell restricted or control securities. The form declares an intent to sell but does not guarantee the sale will happen. It requires the sale to occur within 90 days of filing and imposes volume limitations, typically not exceeding the greater of 1% of outstanding shares or the average weekly trading volume over the preceding four weeks.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.